Search Results - "Parikh, Rahul A"

Immunotherapy in genitourinary malignancies by Mehta, Kathan, Patel, Keyur, Parikh, Rahul A

“…Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic…”
Get full text

Overall survival based on oncologist density in the United States: A retrospective cohort study by Siddappa Malleshappa, Sudeep K, Giri, Smith, Patel, Smit, Mehta, Tapan, Appleman, Leonard, Huntington, Scott F, Passero, Vida, Parikh, Rahul A, Mehta, Kathan D

“…Medically underserved areas (MUA) or health professional shortage areas (HPSA) designations are based on primary care health services availability. These…”
Get full text

High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features by Achkar, Tala, Arjunan, Ananth, Wang, Hong, Saul, Melissa, Davar, Diwakar, Appleman, Leonard J, Friedland, David, Parikh, Rahul A

“…High-dose interleukin-2 (HD IL-2) is used in the treatment of metastatic renal cell carcinoma (mRCC) and has an overall response rate (ORR) of 12-20% and a…”
Get full text

Adjuvant Therapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma by Achkar, Tala, MD, Parikh, Rahul A., MD, PhD

“…This article summarizes the role of adjuvant chemotherapy in muscle-invasive and transitional cell carcinoma of the bladder and upper urinary tract…”
Get full text

Thirty-day readmissions due to Venous thromboembolism in patients discharged with syncope by Siddappa Malleshappa, Sudeep K, Valecha, Gautam K, Mehta, Tapan, Patel, Smit, Giri, Smith, Smith, Roy E, Parikh, Rahul A, Mehta, Kathan

“…A recent study found that approximately 1 in every 6 patients hospitalized for the 1st episode of syncope had an underlying pulmonary embolism (PE). As current…”
Get full text

Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients by Mehta, Kathan, Appleman, Leonard, Wang, Hong, Tarhini, Ahmad A, Parikh, Rahul A

“…Immunotherapy using high dose interleukin-2 (HD IL2) in patients with renal cell carcinoma (RCC) and melanoma is associated with severe toxicities. The…”
Get full text

Complete biochemical response after pulmonary metastasectomy in prostate adenocarcinoma by Rush, Jonathan, Pai, Reet, Parikh, Rahul A

“…Prostate cancer most commonly metastasizes to bones or lymph nodes, and metastatic prostate cancer is suggestive of disseminated disease. Metastatic disease is…”
Get full text

Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update by Garje, Rohan, Rumble, R Bryan, Parikh, Rahul A

“…ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing…”
Get full text

Improving intermittent androgen deprivation therapy： lessons learned from basic and translational research by Parikh, Rahul A, Pascal, Laura E, Davies, Benjamin J, Wang, Zhou

“…Intermittent androgen deprivation therapy （IADT） is an alternative to continuous androgen deprivation therapy （ADT） in prostate cancer patients with…”
Get full text

Systemic Therapy Update on 177 Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update by Garje, Rohan, Rumble, R Bryan, Parikh, Rahul A

“…ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing…”
Get full text

Reversal of the Warburg phenomenon in chemoprevention of prostate cancer by sulforaphane by Singh, Krishna B, Hahm, Eun-Ryeong, Alumkal, Joshi J, Foley, Lesley M, Hitchens, T Kevin, Shiva, Sruti S, Parikh, Rahul A, Jacobs, Bruce L, Singh, Shivendra V

“…Inhibition of metabolic re-programming represents an attractive approach for prevention of prostate cancer. Studies have implicated increased synthesis of…”
Get full text

Opana-ER used the wrong way: intravenous abuse leading to microangiopathic hemolysis and a TTP-like syndrome by Amjad, Ali Imran, Parikh, Rahul A.

Get full text

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810 by Appleman, Leonard J, Kim, Se Eun, Harris, Wayne B, Pal, Sumanta K, Pins, Michael R, Kolesar, Jill, Agarwal, Neeraj, Parikh, Rahul A, Vaena, Daniel A, Ryan, Christopher W, Hashmi, Mehmood, Costello, Brian A, Cella, David, Dutcher, Janice P, DiPaola, Robert S, Haas, Naomi B, Wagner, Lynne I, Carducci, Michael A

“…Patients with no evidence of disease (NED) after metastasectomy for renal cell carcinoma are at high risk of recurrence. Pazopanib is an inhibitor of vascular…”
Get full text

Trends of Inpatient Venous Thromboembolism in United States Before and After the Surgeon General's Call to Action by Mehta, Kathan D., Siddappa Malleshappa, Sudeep K., Patel, Smit, Giri, Smith, Wang, Hong, Smith, Roy, Parikh, Rahul A.

“…Venous thromboembolism (VTE) is an important cause of morbidity and mortality in the United States (US). The increasing rates of VTE in the US resulted in the…”
Get full text

Renal Medullary Carcinoma : Case Report of an Aggressive Malignancy with Near-Complete Response to Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy by Amjad, Ali Imran, Ali, Hira, Appleman, Leonard J., Maranchie, Jodi K., Jackman, Stephen V., Parwani, Anil V., Dhir, Rajiv, Roy, Somak, Parikh, Rahul A.

“…Renal medullary carcinoma (RMC) is a rare but aggressive malignancy affecting young individuals with sickle cell trait. Renal medullary carcinoma commonly…”
Get full text

Systemic Therapy Update on 177 Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A by Garje, Rohan, Hope, Thomas A, Rumble, R Bryan, Parikh, Rahul A

Get more information

A prolonged response to platinum‐based therapy in a patient with metastatic urothelial carcinoma harboring a single rearranged and truncated NF2 gene by Achkar, Tala, Ali, Siraj M., Welsh, Allison, Dhir, Rajiv, Gollin, Susanne M., Parikh, Rahul A.

“…Tumor genome sequencing has become an invaluable resource in determining targets for new therapies. In this report, we describe the case of a patient with…”
Get full text

Metastatic Plasmacytoid Bladder Cancer Harboring a CDH-1 Mutation and Producing High Levels of CA 19-9. A Case Report and Literature Review by Telfah, Mohammad, Parikh, Rahul A, Zhang, Da, Kasi, Anup

“…BACKGROUND Plasmacytoid urothelial carcinoma (PUC) is a rare and aggressive variant of urothelial cancers. Herein, we report a patient with CDH-1 mutated PUC…”
Get full text

Targeted inhibition of ATR or CHEK1 reverses radioresistance in oral squamous cell carcinoma cells with distal chromosome arm 11q loss by Sankunny, Madhav, Parikh, Rahul A., Lewis, Dale W., Gooding, William E., Saunders, William S., Gollin, Susanne M.

“…Oral squamous cell carcinoma (OSCC), a subset of head and neck squamous cell carcinoma (HNSCC), is the eighth most common cancer in the U.S.. Amplification of…”
Get full text

Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant by Khan, Qamar J, Bivona, Cory R, Martin, Grace A, Zhang, Jun, Liu, Ben, He, Jianghua, Li, Kevin H, Nelson, Maggie, Williamson, Stephen, Doolittle, Gary C, Sun, Weijing, Mudaranthakam, Dinesh Pal, Streeter, Natalie R, McGuirk, Joseph P, Al-Rajabi, Raed, Hoffmann, Marc, Kasi, Anup, Parikh, Rahul A, Zhong, Cuncong, Mitchell, Laura, Pessetto, Ziyan Y, Pathak, Harsh, Ghosh, Arnab, LaFaver, Stephanie, Sharma, Priyanka, Godwin, Andrew K

“…The durability of the antibody response to COVID-19 vaccines in patients with cancer undergoing treatment or who received a stem cell transplant is unknown and…”
Get more information